News Briefs


Mt. Sinai Spinout Vivaldi Biosciences Nets $23M in Startup Financing

Influenza vaccine developer Vivaldi Biosciences, a spinout of the Mount Sinai School of Medicine in New York, said this week that it has received commitments for $23 million in Series A financing, of which $18.85 million has been funded.

Bay City Capital and NGN Capital co-led the financing, with participation by the New York City Investment Fund and Alexandria Real Estate Equities. The remaining commitments are to be funded subject to achievement of certain milestones, Vivaldi said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.